News & Updates

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

11 Apr 2025 by

In the long-term maintenance period after percutaneous coronary intervention (PCI), monotherapy with clopidogrel appears to work better than aspirin at preventing major adverse cardiac and cerebrovascular events in Asian patients at high risk of recurrent ischaemic events, as shown in the open-label SMART-CHOICE 3 trial conducted in South Korea.

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

11 Apr 2025

Hepatitis A vaccine may be safely administered to children on biologic therapy

11 Apr 2025

Paediatric patients with autoinflammatory diseases undergoing treatment with canakinumab and tocilizumab can be safely vaccinated against hepatitis A, according to a prospective interventional study.

Hepatitis A vaccine may be safely administered to children on biologic therapy

11 Apr 2025

X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy

10 Apr 2025 by

Interim data from the ongoing 7-year open-label extension (OLE) of the phase IIb X-TOLE study reflect the long-term efficacy and safety of azetukalner, an investigational, potent Kv7 potassium channel opener, for the treatment of adults with focal epilepsy.

X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy

10 Apr 2025

BPaL regimen tied to liver injury

10 Apr 2025

The overall risk of drug-induced liver injury (DILI) with the pretomanid, bedaquiline and linezolid (BPaL) regimen is lower compared with the isoniazid, rifampin, pyrazinamide and ethambutol (HRZE) regimen, a study has shown. However, the association between BPal and DILI remains significant, suggesting the need for careful monitoring during treatment.

BPaL regimen tied to liver injury

10 Apr 2025

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

10 Apr 2025 by

Elderly patients with aortic stenosis who received dapagliflozin after transcatheter aortic-valve implantation (TAVI) had better outcomes than those who did not receive the drug, according to the DapaTAVI* trial presented at ACC.25.

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

10 Apr 2025

Original New Drug Application Approvals by US FDA (16-31 March 2025)

10 Apr 2025

New drug applications approved by US FDA as of 16-31 March 2025 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.

Original New Drug Application Approvals by US FDA (16-31 March 2025)

10 Apr 2025

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

09 Apr 2025

Women are more likely than men to fill prescriptions for statin, particularly high-intensity dosages, after undergoing coronary artery bypass surgery (CABG), with statin therapy equally effective at reducing mortality for both sexes, according to a study.

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

09 Apr 2025

Semaglutide makes STRIDEs in peripheral artery disease

09 Apr 2025 by

Patients with symptomatic peripheral artery disease and type 2 diabetes see notable improvements in their walking capacity and quality of life with once-weekly semaglutide injections in the phase 3b STRIDE study.

Semaglutide makes STRIDEs in peripheral artery disease

09 Apr 2025

Amlodipine makes up half of CCB overdoses; verapamil, diltiazem remain most toxic

09 Apr 2025 by

Among the cases of calcium channel blocker (CCB) overdose, dihydropyridines are the most common, with amlodipine accounting for nearly half. On the other hand, more severe toxicities occur with the use of verapamil and diltiazem.

Amlodipine makes up half of CCB overdoses; verapamil, diltiazem remain most toxic

09 Apr 2025

DUET boosts LXB potential in narcolepsy or idiopathic hypersomnia

08 Apr 2025 by

Data from the phase IV DUET* study presented at AAN 2025 reinforce the potential of low-sodium oxybate (LXB) for the treatment of narcolepsy or idiopathic hypersomnia (IH).

DUET boosts LXB potential in narcolepsy or idiopathic hypersomnia

08 Apr 2025

News & Updates

Filter by Specialty:

Specialty:

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

Clopidogrel outshines aspirin for secondary prevention in high-risk PCI patients

Hepatitis A vaccine may be safely administered to children on biologic therapy

Hepatitis A vaccine may be safely administered to children on biologic therapy

X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy

X-TOLE OLE interim analysis shows long-term efficacy of novel agent for focal epilepsy

BPaL regimen tied to liver injury

BPaL regimen tied to liver injury

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

Dapagliflozin after TAVI improves outcomes in elderly patients with aortic stenosis

Original New Drug Application Approvals by US FDA (16-31 March 2025)

Original New Drug Application Approvals by US FDA (16-31 March 2025)

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

Women more likely than men to receive high-intensity statins for secondary prevention post-CABG

Semaglutide makes STRIDEs in peripheral artery disease

Semaglutide makes STRIDEs in peripheral artery disease

Amlodipine makes up half of CCB overdoses; verapamil, diltiazem remain most toxic

Amlodipine makes up half of CCB overdoses; verapamil, diltiazem remain most toxic

DUET boosts LXB potential in narcolepsy or idiopathic hypersomnia

DUET boosts LXB potential in narcolepsy or idiopathic hypersomnia